0.721 USD
-0.01 (-0.96%)
0.721 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to BRNS. BRNS was compared to 525 industry peers in the Biotechnology industry. While BRNS has a great health rating, there are worries on its profitability. BRNS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- BRNS had negative earnings in the past year.
- In the past year BRNS has reported a negative cash flow from operations.
- BRNS had negative earnings in 4 of the past 5 years.
- In the past 5 years BRNS always reported negative operating cash flow.
1.2 Ratios
- BRNS has a Return On Assets (-55.93%) which is in line with its industry peers.
- BRNS has a Return On Equity (-72.31%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.93% | ||
| ROE | -72.31% | ||
| ROIC | N/A |
ROA(3y)-23.44%
ROA(5y)-24.68%
ROE(3y)-28.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BRNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BRNS has more shares outstanding
- The number of shares outstanding for BRNS has been increased compared to 5 years ago.
- BRNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -3.60, we must say that BRNS is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -3.60, BRNS perfoms like the industry average, outperforming 44.38% of the companies in the same industry.
- There is no outstanding debt for BRNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.6 |
ROIC/WACCN/A
WACC9.33%
2.3 Liquidity
- BRNS has a Current Ratio of 8.04. This indicates that BRNS is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of BRNS (8.04) is better than 74.48% of its industry peers.
- BRNS has a Quick Ratio of 8.04. This indicates that BRNS is financially healthy and has no problem in meeting its short term obligations.
- BRNS has a Quick ratio of 8.04. This is in the better half of the industry: BRNS outperforms 74.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.04 | ||
| Quick Ratio | 8.04 |
3. Growth
3.1 Past
- BRNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.12%.
- Looking at the last year, BRNS shows a very strong growth in Revenue. The Revenue has grown by 1766.46%.
- Measured over the past years, BRNS shows a quite strong growth in Revenue. The Revenue has been growing by 16.92% on average per year.
EPS 1Y (TTM)-18.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)1766.46%
Revenue growth 3Y282.26%
Revenue growth 5Y16.92%
Sales Q2Q%-100%
3.2 Future
- Based on estimates for the next years, BRNS will show a small growth in Earnings Per Share. The EPS will grow by 1.29% on average per year.
- BRNS is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y1.29%
EPS Next 2Y3.23%
EPS Next 3Y1.29%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for BRNS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRNS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.23%
EPS Next 3Y1.29%
5. Dividend
5.1 Amount
- No dividends for BRNS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BARINTHUS BIOTHERAPEUTICS PL / BRNS FAQ
What is the ChartMill fundamental rating of BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?
ChartMill assigns a fundamental rating of 3 / 10 to BRNS.
What is the valuation status for BRNS stock?
ChartMill assigns a valuation rating of 0 / 10 to BARINTHUS BIOTHERAPEUTICS PL (BRNS). This can be considered as Overvalued.
How profitable is BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?
BARINTHUS BIOTHERAPEUTICS PL (BRNS) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for BRNS stock?
The Earnings per Share (EPS) of BARINTHUS BIOTHERAPEUTICS PL (BRNS) is expected to grow by 1.29% in the next year.